在HER2阳性胆囊癌与高瘤突变负担的HER2阳性胆囊癌中对Pembrolizumab的异常反应
Akinori Sasaki1,2, Satoru Nakajima3, Yasuaki Motomura3
1Department of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Toudaijima, Urayasu, Chiba, 279-0001, Japan. akinorisasaki6@gmail.com.
Journal of gastrointestinal cancer
|September 10, 2024
概括
这项研究提出了一个案例,pembrolizumab有效地治疗了具有HER2-阳性和高瘤突变负担 (TMB-H) 特征的先进胆道管癌,显示出显著的瘤缩.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 晚期胆管癌 (胆管癌) 由于治疗选择有限,预后不佳.
- 基因型导向疗法正在出现,但针对性治疗的临床数据仍然很少.
- 人类表皮生长因子受体-2 (HER2) 阳性和高瘤突变负担 (TMB-H) 胆管癌存在独特的治疗挑战.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
